N ot long ago, the ability of the brain to restore function through regeneration of neural elements was thought to be nonexistent. It is now known that not only does some regenerative capacity exist, but implanted cells can integrate into the host brain, survive, and reverse neurological deficits. Neural stem cells, fetal transplants, immortalized cell lines, and bone marrow stromal cells show promise in experimental models of neurological disease including stroke. Although it is clear that transplanted cells function, the mechanism by which neurological deficits might improve is less certain. Transplanted cells may preserve existing host cells and connections through secretion of trophic factors; establish local connections that enhance synaptic activity; provide a bridge for host axonal regeneration; or actually replace cellular elements. Several observations from animal and human studies of cell therapy support the possibility that transplanted cells exert at least some of their effect through cellular replacement.
In the early stages of brain development, implanting neural stem cells leads to replacement of multiple cellular elements including neurons and glia. 1 Thus, the potential for cell replacement exists, but whether it persists into adulthood is uncertain. Models of Parkinson's disease (PD) provide the most direct support for cell replacement as an important effect of cell therapy. Fetal ventral mesencephalic neurons grafted into the striatum in animal models of PD restore dopamine levels and improve function. 2 Similar grafts outside the striatum fail to achieve clinical benefit. In humans, such fetal grafts produce clinical benefit 3 that accrues gradually rather than immediately, suggesting an accumulation of synaptic connections that eventually results in sufficient dopaminergic transmission to improve neurological deficits. Autopsy findings in patients receiving fetal grafts demonstrate implanted cell survival as well as axon growth and synaptic connections 4 . Additional support comes from positron-emission tomography studies showing a correlation between clinical improvement and increased uptake of [ 18 F]fluorodopa in the striatum. This favors the concept that the response to grafting is mediated by direct activity of the transplanted cells replacing the function of the degenerating dopaminergic cells of the host nigro-striatal pathway.
The challenge of cell replacement for treatment of stroke is in some ways similar to that for PD but in other ways is very different. Like PD, the injury is focal but the neuronal loss typically involves many more cell types and neurotransmitters. Neural pathways are more complex, and the likelihood of implanted cells forming appropriately directed connections necessary to restore function seems remote, unless guided by the host brain. Despite the potential pitfalls, treatment of focal ischemia in animals has demonstrated promising results. Fetal cortical grafts placed in adult neocortex following ischemia make connections with host neurons including cortex, thalamus, and subcortical nuclei. 5 Behavioral improvement occurs in response to these grafts when animals are exposed to an enriched environment. Neuronal cells derived from a human teratocarcinoma cell line (NT2 cells) implanted into the striatum following infarction survive and integrate into the host brain, growing axons and making synaptic connections. 6 Neurological deficits due to stroke are reversed by implantation. 7 The clinical benefit occurs only when a critical number of cells are transplanted, ensuring adequate cell survival. The fact that response depends on the number of cells transplanted suggests the benefit may be mediated by cell replacement.
Extrapolating the results of cell implantation in animal models of stroke to humans is problematic, particularly because of the relative lack of adequate primate stroke models. Unlike PD, in which the motor manifestations of striatal lesions mimic the human disease, deficits in animals due to ischemia are more difficult to compare with human stroke. The first human trial of cell therapy for stroke included 12 patients treated with LBS neurons derived from a teratocarcinoma cell line. 8 This trial was not designed to examine efficacy, but improvement in some patients on the European Stroke Scale scores and NIHSS scores was observed. As in PD, positron-emission tomography studies showed increased metabolic activity in the area of the grafts in several patients 6 and 12 months after implantation. 9 The results of an autopsy in one patient 18 months after implantation documented survival of transplanted neuronal cells. 10 Taken together, these data support the concept that activity of implanted cells is responsible for clinical changes. Further studies are needed to more precisely determine the role of cell replacement-whether the implanted cells form new neural pathways, make local connections, or work by neurohumoral mechanisms.
In the end it is likely that multiple mechanisms contribute to the effect of cell transplantation. Trophic factors may be necessary to promote survival and integration of grafted cells. Implanted cells may also induce host responses that both promote function of the graft and directly contribute to neurological recovery. Although the prospect of replacing brain damaged by ischemia appears daunting, initial experience in this field suggests it is not only possible but plausible.
Stem Cells: Do They Replace or Stimulate?
David Howells, BSc(Hons), PhD I n 2002, more than 6000 articles were published on stem cell biology. Many argued that the importance of these cells lies in their potential to provide transplants for treatment of diseases such as stroke, Parkinson's disease, and spinal cord injury. The fervor is such that human embryos have been cloned, despite substantial ethical concerns, with the justification that "therapeutic cloning" will provide the stem cells needed for widespread transplantation for incurable diseases.
Stem cells prepared from human bone marrow, 1 neuronal progenitor cells from adult rat dentate gyrus, 2 and embryonic human forebrain 3 all engraft successfully within the brain parenchyma and can differentiate into neurons. 2 Surprisingly these engrafted cells can migrate to join existing neural stem cell migratory pathways, 1, 3 and when the brain is injured, migration is redirected specifically to the site of damage. 4 After stroke in rodents, stem cells derived from bone marrow induce functional recovery measured by rotarod, adhesive-removal, and modified neurologic severity score tests when implanted into striatum 5 or cortex 6 or after intra-arterial infusion. 7 Importantly, these improvements were noted when implantation occurred up to 14 days 7 after stroke, were enhanced by brain-derived neurotrophic factor, 8 and were achieved when very few implanted cells expressed neural markers 9 and still retained a relatively undifferentiated morphology. 6 Importantly, despite marked functional improvements, the infarcts do not get smaller. 5 This latter observation would appear to exclude the possibility that the stem cells secrete neuroprotective factors that enhance survival of neurons susceptible to infarction.
These observations have led to speculation that increased host plasticity rather than differentiation and integration of new neurons must account for the observed improvements. 6, 9 The idea of host CNS regenerative responses is not new, but their form and functional significance have remained contentious. At the start of the 20th century, Ramon y Cajal was among the first to study neurite sprouting after brain and spinal injury but decided that these host responses were aborted attempts at reconstruction of severed pathways with little functional significance. This perception changed little until the late 1960s, when Raisman observed that axons in neighboring undamaged pathways could send out additional axonal branches or "collateral sprouts" to reinnervate the septum after it had been denervated.
Interestingly, such observations of host plasticity played a key role in promoting transplantation as a treatment for neurological disease, and today intrastriatal implants of fetal The opinions expressed in this editorial are not necessarily those of the editors or of the American Stroke Association. dopaminergic neurons are viewed by many as a moderately successful way of alleviating the symptoms of Parkinson's disease. However, as in stem cell transplants for stroke, there is also a body of evidence to suggest that host responses may play a significant role in the functional recovery observed after dopaminergic implants.
Autologous adrenal medullary implants in particular were enthusiastically performed in several countries. However, they have been found to be of only mild benefit in less than half of the transplanted patients, and even in patients who improved, subsequent autopsies consistently demonstrated little or no survival of adrenal grafts. The feature that seemed to best correlate with the clinical improvement in animals and man was the presence of peri-wound host dopaminergic sprouting, 10 which has been shown to be a consequence of surgical injury to the striatum and dependent on neurotrophins and growth factors supplied by activated microglia and macrophages. 11 Is enhancement of such host axonal sprouting responsible for stem cell-induced recovery in animal models of stroke?
It would seem prudent to conclude that although stem cell grafts to treat stroke are in their infancy, they do appear to be able to foster functional improvement in animal models of stroke. However, their mechanism of action is far from clear. Perhaps our greatest challenge will be to establish the proportional significance of all mechanisms and fine-tune our treatments to provide the greatest benefit for the victims of stroke.
